stockrowLakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +198.9%
- Free cash flow
- +18.2%
Quarter to June 2026, against a year earlier
Follow LKFT
Alert me
Lakefront Biotherapeutics - Sponsored ADR (LKFT) Return on equity
Lakefront Biotherapeutics - Sponsored ADR's return on equity over the twelve months to 30 June 2026 was 0.00%, down 10.7 percentage points from fiscal 2025 (10.7%). Over the past ten years it has ranged from −38.7% (fiscal 2015) to 10.7% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 10.7% | 8.08 |
| FY2024 | 2.60% | (5.46) |
| FY2023 | 8.06% | 16.00 |
| FY2022 | −7.94% | (3.99) |
| FY2021 | −3.95% | 7.18 |
| FY2020 | −11.1% | (18.34) |
| FY2019 | 7.21% | 9.89 |
| FY2018 | −2.68% | 10.51 |
| FY2017 | −13.2% | (22.79) |
| FY2016 | 9.60% | 48.31 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BHVN Biohaven Ltd. compare | 940.5% |
| AUPH Aurinia Pharmaceuticals Inc compare | 61.4% |
| VCEL Vericel Corporation compare | 9.44% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | 0.00% |
| SEPN Septerna, Inc. compare | −6.34% |
| PVLA Palvella Therapeutics, Inc. compare | −46.6% |
| IMNM Immunome, Inc. compare | −64.0% |
| ZYME Zymeworks Inc. compare | −72.3% |
| VERA Vera Therapeutics, Inc. compare | −91.8% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on LKFT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement